Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MRNA vs BIIB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
BIIB Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)
BIIB Overall Winner
6-Pillar Tally: MRNA 2 – 4 BIIB
Matrix Metrics: MRNA 3 – 7 BIIB
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).
- Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. MRNA 46.8/100 HOLD) and 0.27β · 36% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MRNA vs BIIB
MRNA
Moderna, Inc. Common Stock
$215.96
-3.32% 1D
Market Cap
$93.6B
TTM Revenue
$2.52B
Forward P/E
23.0x
Beta / 30D Vol
2.35β · 101% Vol
Unified Composite Score
46.8
HOLD
Tech 41.0
Fund 50.0
Flow 67.0
Mom 41.1
Weinstein Technical Phase
Neutral · Hold
BIIB
Head-to-Head Winner
Biogen Inc. Common Stock
$252.72
-0.27% 1D
Market Cap
$37.0B
TTM Revenue
$10.3B
Forward P/E
15.6x
Beta / 30D Vol
0.27β · 36% Vol
Unified Composite Score
50.2
HOLD
Tech 45.0
Fund 52.0
Flow 64.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (MRNA 2 – 4 BIIB)
1. Valuation Multiples
BIIB
Forward P/E
23.0x
15.6x
Trailing P/E
23.0x
109.9x
PEG Ratio
N/M
3.45x
EV / Revenue
38.3x
4.2x
2. Growth & Scale
MRNA
Revenue Growth (YoY)
+29.2%
+10.6%
Earnings Growth (YoY)
-85.1%
-84.8%
TTM Revenue (USD)
$2.52B
$10.3B
Market Cap
$93.6B
$37.0B
3. Profitability & Quality
BIIB
Gross Margin
-42.0%
75.8%
Operating Margin
-80.8%
23.5%
Net Profit Margin
-110.5%
3.4%
Return on Equity (ROE)
-34.5%
1.9%
4. Balance Sheet & Cash Flow
BIIB
Cash Generation (TTM)
-$2.04B
$1.64B
Cash Flow Margin
-81.0%
16.0%
Net Cash / Leverage
$3.03B Net Debt (0.62x D/E)
$6.50B Net Debt (0.41x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BIIB
Options Structure Phase
CONSOLIDATION
CONSOLIDATION
Current IV / %ile
70.5% (30th %ile)
18.4% (6th %ile)
Put/Call OI Skew
1.12x (Balanced)
0.77x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
MRNA
OpEx & R&D Intensity
38.8% of Rev ($980M)
52.3% of Rev ($5.39B)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Scale & Operating Efficiency Moat
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - General Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MRNA (3) vs BIIB (7)| Institutional Metric | MRNA | BIIB | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $93.6B | $37.0B | MRNA | |
| Trailing P/E Ratio | 23.0x | 109.9x | MRNA | |
| Forward P/E Ratio | 23.0x | 15.6x | BIIB | |
| Revenue Growth (YoY) | +29.2% | +10.6% | MRNA | |
| Operating Margin (TTM) | -80.8% | 23.5% | BIIB | |
| Net Profit Margin | -110.5% | 3.4% | BIIB | |
| Return on Equity (ROE) | -34.5% | 1.9% | BIIB | |
| 52-Week Range Position | 75% ($22–$281) | 92% ($160–$261) | BIIB | |
| Beta / 30D Volatility | 2.35β · 101% Vol | 0.27β · 36% Vol | BIIB | |
| Unified Institutional Score | 46.8 / 100 (HOLD) | 50.2 / 100 (HOLD) | BIIB | |
| Trailing 12M Revenue (USD) | $2.52B | $10.3B | Scale | |
| Gross Profit Margin (TTM) | -42.0% | 75.8% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 38.3x EV/Rev | 3.45x PEG · 4.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$2.04B ($3.03B Net Debt (0.62x D/E)) | $1.64B ($6.50B Net Debt (0.41x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BIIB +9.57 pp
3M Horizon
MRNA +224.1 pp
6M Horizon
MRNA +317.19 pp
1Y Horizon
MRNA +711.79 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | BIIB Revenue | MRNA Op. Margin | BIIB Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $140M | $13.4B | -306.0% | 43.8% | BIIB |
| FY2019 | $60M | $14.4B | -906.8% | 49.0% | BIIB |
| FY2020 | $800M | $13.4B | -95.0% | 33.8% | BIIB |
| FY2021 | $18.5B | $11.0B | 72.0% | 25.9% | MRNA |
| FY2022 | $19.3B | $10.2B | 48.9% | 29.9% | MRNA |
| FY2023 | $6.85B | $9.84B | -61.9% | 11.8% | BIIB |
| FY2024 | $3.24B | $9.68B | -121.9% | 16.9% | BIIB |
| FY2025 | $1.94B | $9.89B | -158.1% | 13.1% | BIIB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MRNA
CONSOLIDATION
Current IV
70.5%
IV Percentile
30th %ile
Put/Call OI Skew
1.12x (Balanced)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BIIB
CONSOLIDATION
Current IV
18.4%
IV Percentile
6th %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MRNA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
38.8% of Rev ($980M)
90D Engineering Disclosures
0 Published · mRNA Therapeutics
BIIB Moat Profile
Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
OpEx & R&D Reinvestment
52.3% of Rev ($5.39B)
90D Engineering Disclosures
0 Published
Investor FAQ MRNA vs BIIB Key Questions & Quantitative Answers
As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 46.8/100 (HOLD) at $215.96 (23.0x Forward P/E, -80.8% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Growth vs. Quality Trade-Off: BIIB earns the overall head-to-head edge with a stronger Unified Composite Score (50.2/100 HOLD vs. MRNA 46.8/100 HOLD) and 0.27β · 36% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while BIIB shifted -26.5%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.
BIIB screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 38.3x EV/Revenue (-81.0% FCF margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus BIIB (1.9% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 70.5% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 1.12x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.35β · 101% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BIIB vs MRNA · Reverse Pair
MRNA vs NVAX
· Sector Peer
MRNA vs BNTX
· Sector Peer
MRNA vs ZM
· Sector Peer
BIIB vs REGN
· Sector Peer
BIIB vs AMGN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem